Guide

Tirzepatide Side Effects Week by Week: What the Trials Recorded

Gastrointestinal effects cluster in the first weeks after each dose increase and ease as the body adapts. In SURMOUNT-1 nausea affected about 29% of participants, diarrho

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published 2026-08-03Updated 2026-08-03Sources captured 2026-08-03Medically reviewed not yet — why

Direct answer

Gastrointestinal effects cluster in the first weeks after each dose increase and ease as the body adapts. In SURMOUNT-1 nausea affected about 29% of participants, diarrhoea 23% and vomiting 13%, and between 4.3% and 7.1% discontinued for an adverse event depending on dose.

Answer last reviewed: 2026-08-03

What did the trials actually record?

Adverse events in SURMOUNT-1, by frequency
Event	Tirzepatide 15 mg	Placebo	Pattern over time
Nausea	~29%	~9%	Peaks in the days after each increase
Diarrhoea	~23%	~7%	Similar pattern
Constipation	~17%	~9%	More persistent than nausea
Vomiting	~13%	~2%	Concentrated at escalation
Discontinued for an adverse event	4.3–7.1%	~2.6%	Mostly during titration

Why do the effects cluster where they do?

Tirzepatide slows gastric emptying. Each dose increase is a new stimulus the gut adapts to over days to weeks, which is why symptoms concentrate in the window after an escalation and settle at a stable dose. It is also why labelling directs increases as tolerated rather than on a fixed calendar.

The financial consequence nobody mentions

Discontinuation happens during titration — the same window a prepaid twelve-month plan commits you through. A plan saving $348 over a year is a poor trade if you stop in month three and recover nothing.

Ask what is refunded before you prepay. It is on our commitment terms field page because most providers do not answer it.

What is a reason to contact a prescriber rather than wait?

Labelling carries warnings for pancreatitis, gallbladder disease, severe gastrointestinal disease, acute kidney injury from dehydration, and hypoglycaemia when combined with insulin or a sulfonylurea. There is a boxed warning for thyroid C-cell tumours, and a contraindication in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.

Severe or persistent abdominal pain, persistent vomiting, or an inability to keep fluids down are reasons to seek care rather than to wait it out. We are not going to publish a self-management protocol for those; that is a clinical conversation.

What each pivotal trial established
Trial	Population	Result	Duration
SURMOUNT-1	Obesity or overweight, no diabetes	22.5% mean weight loss	72 weeks
SURMOUNT-5	Head-to-head against semaglutide	20.2% vs 13.7%	72 weeks
SURPASS-2	Type 2 diabetes	Superior HbA1c reduction	40 weeks
SURMOUNT-OSA	Obstructive sleep apnoea with obesity	Large AHI reduction	52 weeks

Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.

How does every provider score on the six tests?

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

Every provider against the six testsComputed from the dataset on 2026-08-03 · 30 providers evaluated

Every provider against the six tests
Provider	Captured at source	Publishes a maintenance-dose price	One published structure	Names its fulfilling pharmacy	Answered all four disclosure questions	No figure we had to withdraw	Score
Mochi Health	Yes	Yes	Yes	Yes	—	Yes	5 of 6
NexLife	Yes	Yes	Yes	Yes	—	Yes	5 of 6
Fifty 410	Yes	—	Yes	—	—	Yes	3 of 6
LillyDirect	Yes	—	Yes	—	—	Yes	3 of 6
Trimi	Yes	—	Yes	—	—	Yes	3 of 6
Calibrate	—	—	Yes	—	—	Yes	2 of 6
Enhance.MD	—	—	Yes	—	—	Yes	2 of 6
Form Health	—	—	Yes	—	—	Yes	2 of 6

Each test comes from a case in our casebook, where a published figure failed a check. The table is generated from the records, not written.

The result, as of 2026-08-03

No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.

That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.

Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.

Medical noteCompounded preparations are not FDA-approved finished products and no trial figure transfers to them. Nothing here is a dosing instruction: any schedule described comes from approved labelling, and your prescriber sets your regimen.

Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information

Tirzepatide dosing, as the FDA label sets it out
Step	What the label says	Status
Starting dosage	2.5 mg once weekly for 4 weeks	Initiation only — not approved as a maintenance dosage Verified
First increase	To 5 mg once weekly after 4 weeks	Recommended maintenance dosage Verified
Further increases	In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response	A minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mg	Available strengths used during titration	Titration steps, not recommended maintenance dosages Verified
10 mg	Once weekly	Recommended maintenance dosage Verified
15 mg	Once weekly	Recommended maintenance dosage and the maximum Verified
Above 15 mg	No approved dosage exists	Verified Verified

Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.

Why 'cheapest' needs a definition attached

Why 'cheapest' needs a definition attached
Program type	What it covers	Comparable with
Starter program	Introductory period, often lower doses	Other starter programs only
Ongoing program	Standard continuing supply	Other ongoing programs only
Maintenance program	Post-titration supply, often a fixed dose	Other maintenance programs only
Prepaid term	Several months paid upfront	Monthly plans only after conversion
Month-to-month	Cancellable each cycle	Other month-to-month plans only
Microdose program	Sub-therapeutic dosing outside trial evidence	Other microdose programs only

Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Frequently asked questions

How long do tirzepatide side effects last?

They cluster in the days to weeks after each dose increase and typically ease at a stable dose. The trials did not publish a fixed duration because it varies.

What percentage of people stop because of side effects?

In SURMOUNT-1, between 4.3% and 7.1% discontinued for an adverse event depending on dose, against about 2.6% on placebo.

Which side effect is most common?

Nausea, at about 29% on the 15 mg dose against about 9% on placebo.

When should I contact a prescriber?

Severe or persistent abdominal pain, persistent vomiting, or an inability to keep fluids down are reasons to seek care rather than wait.

How rankings are computedCore & Trust
All-in cost toolTools
Price records, machine-readableData
Tirzepatide for Type 2 DiabetesResearch
Tirzepatide and Sleep Apnea: Evidence and FDA StatusJournal
Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
Tirzepatide vs Semaglutide: What the Head-to-Head Trial ShowsJournal
Tirzepatide and Type 2 Diabetes PreventionResearch
Tirzepatide and PCOS: What Evidence Exists?Research
Tirzepatide and Heart Failure With Preserved Ejection FractionJournal

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Rank. “Tirzepatide Side Effects Week by Week: What the Trials Recorded.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-side-effects-week-by-week-2026/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error